Zepatier Tops Other Hepatitis C Drugs in Safety Comparison


“The general conclusion is that Zepatier looks safer than Sovaldi, just based on clinical trial information,” Advera Chief Product Officer Bob Kyle said in a report on FiercePharma. “(But) anything can change once the real world data starts to come through. It’s something to keep an eye on in post-marketing data.”

Interferon was previously used for HCV patients, but it came with unbearable side effects. Sovaldi was launched in 2013 with lesser side effects compared with interferon. Sovaldi proved to have cure rates up to 90% with just 12 to 24 week treatment durations, as opposed to interferon regimens of 24 to 48 weeks.

With the launch of Harvoni in October 2014 with an 8 to 12 week treatment regimen, it eliminated the use of interferon. Harvoni also became the fastest selling drug post development. Combined, Sovaldi and Harvoni reached sale revenues of $12.5 billion (2014) and $14 billion (first 9 months of 2015) since launch.

Although Zepatier performed almost equally as well treating patients in clinical trials, Harvoni was found to perform better compared with Zepatier and Sovaldi in previously treated HCV patients.

AbbVie’s interferon-free Viekira Pak also added to the crowded HCV treatment market. It is used without ribavirin for HCV genotype 1 and 4 patients. In 2015, it was reported that Viekira Pak revenues were $227 million within the United States and $158 million internationally.

"Our clinical development program for Zepatier is among the largest and most comprehensive for chronic HCV treatment,” Merck spokeswoman Sarra Herzog told FiercePharma. “It included studies dedicated to patient populations where significant unmet medical need still exists, such as prior treatment failures, as well as those living with co-morbid conditions, including HIV infection and advanced chronic kidney disease. We believe our clinical data and FDA-approved prescribing information demonstrate the value of Zepatier."
 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Direct-to-consumer prescription drug advertising increased from $1.3 billion to $6 billion over the past 20 years, particularly for high-cost biologics and cancer immunotherapies.
A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.
Doug Long, vice president of Industry Relations at IQVIA, discusses rebate reform surrounding Medicare Part D and Part B in an interview with Specialty Pharmacy Times.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$